Literature DB >> 15356969

Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies.

S Sund1, A V Reisaeter, H Scott, T E Mollnes, T Hovig.   

Abstract

BACKGROUND: The specific role of monocytes/macrophages (MO) in kidney graft rejection is not yet fully elucidated. In a recent protocol biopsy study of living-donor recipients, we demonstrated massive capillary influx of MO, associated with severe complement activation and acute rejection (AR) 1 week after transplantation [Sund et al.]. To gain further insight into the possible relationship between MO and complement activation, we analyzed glomerular and interstitial MO in these biopsies.
METHODS: Twenty-seven protocol biopsies were stained with antibodies to calprotectin (L1) and CD68 as markers for MO. Cells were counted as an average number per glomerulus and as an average number per defined visual field in the interstitium. Polymorphonuclear leukocytes (PMN) were counted in glomeruli and interstitium by light microscopy. Baseline specimens from 10 of the patients served as controls. The results were compared with data on deposition of complement from the foregoing study, and with histopathologic and clinical data on AR.
RESULTS: Cases with diffuse C4d deposition in peritubular capillaries consistent with acute antibody-mediated rejection (AbAR) (n = 4) had significantly higher numbers of intraglomerular MO than the other protocol biopsies (L1: median 20.7 vs 3.6, p = 0.0002; CD68: median 10.1 vs. 2.0, p = 0.0008). With a cut-off of 10 L1-positive and 6 CD68-positive MO, the specificity for the diagnosis of AbAR was 96% and 91%, respectively. The number of interstitial MO was significantly higher in patients with AR than in those without, but in contrast to glomerular MO, interstitial MO could not discriminate between complement positive and negative AR. The number of glomerular and interstitial PMNs was significantly higher in the AbAR group than in the other protocol biopsies.
CONCLUSIONS: The strong correlation between complement activation and early glomerular influx of MO in the kidney allograft suggests a causal relationship between these 2 events. At 1 week after transplantation, a number of 10 L1-positive and 6 CD68-positive MO per glomerulus indicates AbAR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356969     DOI: 10.5414/cnp62121

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Monocyte infiltration and kidney allograft dysfunction during acute rejection.

Authors:  R Girlanda; D E Kleiner; Z Duan; E A S Ford; E C Wright; R B Mannon; A D Kirk
Journal:  Am J Transplant       Date:  2008-03       Impact factor: 8.086

Review 2.  Dendritic cells and macrophages in the kidney: a spectrum of good and evil.

Authors:  Natasha M Rogers; David A Ferenbach; Jeffrey S Isenberg; Angus W Thomson; Jeremy Hughes
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

3.  Complement 5a receptor inhibition improves renal allograft survival.

Authors:  Faikah Gueler; Song Rong; Wilfried Gwinner; Michael Mengel; Verena Bröcker; Sylvia Schön; Tim Friedrich Greten; Heiko Hawlisch; Thomas Polakowski; Karsten Schnatbaum; Jan Menne; Hermann Haller; Nelli Shushakova
Journal:  J Am Soc Nephrol       Date:  2008-08-27       Impact factor: 10.121

4.  The protein kinase 2 inhibitor tetrabromobenzotriazole protects against renal ischemia reperfusion injury.

Authors:  Sun-O Ka; Hong Pil Hwang; Jong-Hwa Jang; In Hyuk Bang; Ui-Jin Bae; Hee Chul Yu; Baik Hwan Cho; Byung-Hyun Park
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

Review 5.  The specificity of acute and chronic microvascular alterations in renal allografts.

Authors:  Edward J Filippone; John L Farber
Journal:  Clin Transplant       Date:  2013-10-01       Impact factor: 2.863

6.  Immune complex glomerulonephritis following bone marrow transplantation in C3 deficient mice.

Authors:  Thomas R Welch; Lisa W Blystone
Journal:  PLoS One       Date:  2008-10-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.